Arvinas reported FY 2025 revenue of USD 262.6 million and a net loss of USD 80.8 million, alongside R&D expense of USD 285.2 million and G&A expense of USD 95.9 million. Other income was USD 38.0 million and income tax expense was USD 0.3 million. Cash, cash equivalents and marketable securities were USD 685.4 million as of Dec. 31, 2025, which Arvinas said it expects to fund operations into the second half of 2028. On the business side, Arvinas said the FDA accepted its NDA for vepdegestrant in ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer and set a PDUFA action date of June 5, 2026; Arvinas and Pfizer also agreed to jointly select a third party for commercialization and potential future development of vepdegestrant. Pipeline updates included continued Phase 1 development of ARV-102 in Parkinson’s disease with multiple-dose cohort enrollment completed in Q4 2025 and a planned data presentation in Q1 2026, initiation of a Phase 1 trial of ARV-806 in KRAS G12D-mutant solid tumors in Q2 2025 with initial clinical data anticipated in 2026, and ongoing Phase 1 dose escalation for ARV-393 in relapsed/refractory non-Hodgkin lymphoma with updated data planned for the second half of 2026. Arvinas also disclosed workforce reductions of about 33% in April 2025 and an additional 15% in September 2025, and reported USD 3.7 million of restructuring charges related to the two actions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-011226), on February 24, 2026, and is solely responsible for the information contained therein.